as 12-18-2024 11:31am EST
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.
Founded: | 1993 | Country: | United States |
Employees: | N/A | City: | AUSTIN |
Market Cap: | 11.7M | IPO Year: | N/A |
Target Price: | $4.40 | AVG Volume (30 days): | 76.2K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.18 | EPS Growth: | N/A |
52 Week Low/High: | $0.67 - $5.65 | Next Earning Date: | 11-14-2024 |
Revenue: | $8,963,000 | Revenue Growth: | -2.33% |
Revenue Growth (this year): | 11.87% | Revenue Growth (next year): | 79.10% |
AWH Breaking Stock News: Dive into AWH Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
15 days ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
GlobeNewswire
2 months ago
The information presented on this page, "AWH Aspira Women's Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.